Department of Pediatrics, Seoul National University Bundang Hospital, Sungnam, South Korea.
Nephrol Dial Transplant. 2012 Jan;27(1):107-14. doi: 10.1093/ndt/gfr280. Epub 2011 Jun 1.
Subtotal nephrectomy (N) in rats results in progressive hypertension, proteinuria and renal lesions. Renin-angiotensin system blockade initiated at N prevents these changes; treatments failing to reduce hypertension and proteinuria do not.
Ten Munich-Wistar rats underwent 1½ surgical N; eight littermates were pretreated with losartan (L) only for 6 weeks prior to 1½ N (N + L). Pretreated (n = 8; C + L) and untreated controls (C; n = 8) had sham operations.
Over 6 months, N and N + L rats developed ∼80% increase in glomerular filtration rate per nephron over C and C + L, P < 0.001). Hypertension (intra-arterial mean blood pressure 116 ± 6.8 mmHg in N rats versus 102 ± 3.2 in C, 104 ± 8.4 in C + L, and 104 ± 8.4 in N + L rats, P < 0.001 for all) and proteinuria (120 ± 20 mg/day in N versus 39 ± 10 in C, 34 ± 8 in C + L and 35 ± 8 in N + L, P < 0.001 for all) developed only in N. Focal segmental glomerulosclerosis (FSGS) (%) at 6 months was 20 ± 8 in N and 17.5 ± 8 in N + L (ns) and <1 in C and C + L (P < 0.001 versus N and N + L). Interstitial fractional volume (Vv), 4.0 ± 1.7% in C and 4.4 ± 1.6% in C + L (ns), was similarly increased to 7.5 ± 2.5% in N and 9.0 ± 3.9% in N+L (P < 0.04 versus C and C + L). Atrophic tubule Vv was increased by >300% in N and N + L over C and C + L (P < 0.02 for all). Glomerular volume doubled in N and N + L (P < 0.001). Podocyte foot process effacement was greater in N and NL than in C or C + L (P ≤ 0.02 for all). Thus, L given for 6 weeks prior to 1½ N prevented hypertension and proteinuria over the subsequent 6 months without reducing glomerular hypertrophy, hyperfiltration or interstitial, tubular or FSGS lesions or foot process effacement.
These studies dissociated systemic hypertension and proteinuria from the renal lesions in this model. Durable effects of losartan on blood pressure and proteinuria likely represent epigenetic processes.
大鼠的次全肾切除术(N)导致进行性高血压、蛋白尿和肾脏病变。在 N 之前开始的肾素-血管紧张素系统阻断可预防这些变化;未能降低高血压和蛋白尿的治疗则不能。
10 只慕尼黑-威斯特伐利亚大鼠接受了 1½次手术 N;8 只同窝仔鼠在 1½次 N 之前仅用氯沙坦(L)预处理 6 周(N + L)。预处理组(n = 8;C + L)和未处理对照组(C;n = 8)接受假手术。
在 6 个月内,N 和 N + L 大鼠的每个肾单位肾小球滤过率增加了约 80%,而 C 和 C + L 大鼠的肾小球滤过率分别增加了 80%(P < 0.001)。高血压(N 大鼠的动脉内平均血压为 116 ± 6.8 mmHg,而 C 大鼠为 102 ± 3.2 mmHg,C + L 大鼠为 104 ± 8.4 mmHg,N + L 大鼠为 104 ± 8.4 mmHg,所有组均 P < 0.001)和蛋白尿(N 大鼠为 120 ± 20 mg/天,C 大鼠为 39 ± 10 mg/天,C + L 大鼠为 34 ± 8 mg/天,N + L 大鼠为 35 ± 8 mg/天,所有组均 P < 0.001)仅在 N 大鼠中发生。6 个月时局灶节段性肾小球硬化(FSGS)(%)在 N 大鼠中为 20 ± 8,在 N + L 大鼠中为 17.5 ± 8(无统计学意义),在 C 和 C + L 大鼠中 <1(P < 0.001 与 N 和 N + L 大鼠相比)。间质分体积(Vv),C 和 C + L 大鼠分别为 4.0 ± 1.7%(无统计学意义),分别增加至 7.5 ± 2.5%(P < 0.04 与 C 和 C + L 大鼠相比)。N 和 N + L 大鼠的萎缩肾小管 Vv 增加了 >300%(P < 0.02 与 C 和 C + L 大鼠相比)。肾小球体积在 N 和 N + L 大鼠中增加了一倍(P < 0.001)。N 和 N + L 大鼠的足细胞足突融合比 C 和 C + L 大鼠更明显(P ≤ 0.02,所有组)。因此,在 1½次 N 之前给予氯沙坦 6 周可预防随后 6 个月的高血压和蛋白尿,而不会降低肾小球肥大、高滤过或间质、肾小管或 FSGS 病变或足突融合。
这些研究将该模型中的系统性高血压和蛋白尿与肾脏病变区分开来。氯沙坦对血压和蛋白尿的持久影响可能代表了表观遗传过程。